Jynarque 90MG/30MG
Ended Awarded
- Contract number
- 36C24524N0569
- Awardee
-
Otsuka America Pharmaceutical Inc. UEI QKABLBMA8FT9
- Awarding agency
-
Veterans Integrated Service Network 5
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $12,560
Award facts
- Contract value 100% obligated
- $12,559.90 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Pittsburgh, PA 15275, USA
Award details come from SAM.gov/FPDS.
About this award
Otsuka America Pharmaceutical Inc., a specialty pharmaceutical manufacturer headquartered in Rockville, Maryland, was awarded a $12,559.90 firm fixed-price delivery order for Jynarque (tolvaptan) 90mg/30mg by the Department of Veterans Affairs' Veterans Integrated Service Network 5 (VISN 5). The delivery order, issued on May 3, 2024, with an ultimate completion date of May 10, 2024, will be performed in Pittsburgh, Pennsylvania. This award was made without a set-aside designation and falls under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB), reflecting the company's established status as a large pharmaceutical contractor to the VA healthcare system.
This delivery order is issued against Otsuka America Pharmaceutical Inc.'s larger Blanket Purchase Agreement valued at $83.3 million for Jynarque, awarded by the National Acquisition Center with a completion date of March 26, 2026. Jynarque, a medication used to treat autosomal dominant polycystic kidney disease and hyponatremia, represents the company's primary product supplied to the VA. The delivery order supports the Veterans Health Administration's mission to provide specialized pharmaceutical treatments to veterans across multiple integrated service networks nationwide. Otsuka America Pharmaceutical Inc. also maintains a $396 million Federal Supply Schedule contract for pharmaceuticals and hematology-related products, demonstrating its significant capability to supply federal healthcare systems.
Quick answers
Who was awarded contract 36C24524N0569?
36C24524N0569 was awarded to Otsuka America Pharmaceutical Inc. by Veterans Integrated Service Network 5 (Veterans Health Administration) on May 3, 2024.
How much is contract 36C24524N0569 worth?
The government has obligated $12,560 on 36C24524N0569.
Is contract 36C24524N0569 an order under another contract?
Yes. 36C24524N0569 is a delivery order under 36F79720D0099, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C24524N0569 competed?
The extent of competition for 36C24524N0569 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award